市場調査レポート
商品コード
1298581
オーファンドラッグ(希少疾病用医薬品)市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
オーファンドラッグ(希少疾病用医薬品)市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測 |
出版日: 2023年06月14日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2~3営業日
|
世界のオーファンドラッグ(希少疾病用医薬品)市場規模は2022年に1,917億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて12.02%の成長率(CAGR)を示し、2028年までに3,835億米ドルに達すると予測しています。
希少医薬品とは、希少疾患の診断、予防、治療に使用される医薬品を指します。これらの医薬品は、特定の公衆衛生上の要件を満たすために製造され、少数の患者グループ向けに製造されるため、通常、市場は限られています。これらの医薬品は、多くの腫瘍学的、代謝学的、血液学的、免疫学的、感染学的、神経学的疾患に対して有効です。リンパ腫、白血病、嚢胞性線維症、神経膠腫、膵臓がん、卵巣がん、多発性骨髄腫、腎細胞がんなどの医学的疾患は、多くの場合、生命を脅かし、慢性で進行性、退行性、障害性であり、特定の症状に有効な特定の治療法が必要とされます。
がんやその他の希少遺伝性疾患の有病率の増加は、市場の成長を促す重要な要因のひとつです。製薬メーカーは、患者に個別化治療を提供するため、革新的なオーファンドラッグ(希少疾病用医薬品)を開発しています。また、オーファンドラッグの利点に関する大衆の意識の高まりも市場を牽引しています。新しい医薬品メーカーの出現や、伝染病の蔓延を抑制するための政府の有利な政策の実施も、市場の成長に寄与しています。さらに、生物学的オーファンドラッグの開発など、さまざまな製品革新も成長を促す要因となっています。これらの医薬品は、がんなどの疾患を治療し、幹細胞に生じた損傷を回復させることができるため、全体的な需要を大幅に促進しています。その他の要因としては、医療インフラの改善、広範な研究開発活動などがあり、市場をさらに牽引すると予想されます。
The global orphan drugs market size reached US$ 191.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 383.5 Billion by 2028, exhibiting a growth rate (CAGR) of 12.02% during 2023-2028.
Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.
The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.
Biological
Non-Biological
Oncology
Hematology
Neurology
Cardiovascular
Others
Phase I
Phase II
Phase III
Phase IV
Revlimid
Rituxan
Copaxone
Opdivo
Keytruda
Imbruvica
Avonex
Sensipar
Soliris
Others
Hospital Pharmacies
Retail Pharmacies
Online Stores
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global orphan drugs market in 2022?
2. What is the expected growth rate of the global orphan drugs market during 2023-2028?
3. What are the key factors driving the global orphan drugs market?
4. What has been the impact of COVID-19 on the global orphan drugs market?
5. What is the breakup of the global orphan drugs market based on the drug type?
6. What is the breakup of the global orphan drugs market based on the disease type?
7. What is the breakup of the global orphan drugs market based on top selling drugs?
8. What is the breakup of the global orphan drugs market based on the distribution channel?
9. What are the key regions in the global orphan drugs market?
10. Who are the key players/companies in the global orphan drugs market?